GlassScriptPhysician profile
Alexander Chernobelsky
NPI 1043255292
$59,886.50
in general payments reported to CMS, 2019-2025
27 companies · $6,191 in 2025
The $6,191 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,042 · 2020: $6,224 · 2021: $1,350 · 2022: $1,461 · 2023: $1,450 · 2024: $36K · 2025: $6,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $40,860.00 |
| Food and Beverage | $2,950.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45,660.00 | 2020-2025 | (5044) Mcot, Mcot |
| Braemar Manufacturing, LLC | $4,800.00 | 2019 | |
| Abbott Laboratories | $2,970.49 | 2019-2024 | Aveir, Fortify Assura, Accent |
| Amgen INC. | $1,952.43 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,373.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $868.06 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $351.27 | 2019-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $320.70 | 2019-2023 | |
| Pfizer INC. | $305.92 | 2019-2025 | |
| Abiomed | $120.51 | 2024-2025 | Impella |
| Medtronic, INC. | $117.52 | 2021-2024 | Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.65 | 2021-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $107.36 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $106.71 | 2019-2021 | |
| Boston Scientific Corporation | $89.62 | 2019-2023 | Watchman Access System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.18 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $82.41 | 2019-2022 | |
| Cvrx, INC. | $70.31 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.35 | 2019-2023 | Lifevest |
| Cardiva Medical, INC. | $67.12 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Esperion Therapeutics, INC. | $63.58 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $59.75 | 2019-2021 | |
| Novo Nordisk INC | $46.17 | 2022-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $38.33 | 2021 | |
| Acutus Medical, INC. | $26.49 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.23 | 2022 | |
| Medtronic Vascular, INC. | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Chernobelsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.